Proposed Changes Focus on Raising Price Premiums While Cutting Prices for Existing Drugs, According to a New Macroview Update from Decision Resources
WALTHAM, Mass., Feb. 19 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Japan has proposed only modest changes to its pharmaceutical pricing mechanism for 2008 and beyond. The changes reflect the Japanese government's focus on containing healthcare spending.
The most recent proposals do allow for an increase in premiums that can be awarded. For innovative drugs, the premium range will be increased.
"To qualify for this premium in Japan, a product must have clinically useful new mechanisms of action, must be proven to have greater efficacy or improved safety and must demonstrate resultant, improved management of the target indication," said Stuart Bowman, director at Decision Resources. "However, this premium is rarely awarded given the stringent, and less than transparent, qualifying criteria."
The 2008 changes also herald the next round of biannual price cuts. There will likely be extraordinary price cuts for big-selling products, specifically products for which sales have significantly exceeded original (official) sales projections. Likely targets will be angiotensin II antagonists and SSRIs.
About Macroview from Decision Resources
Macroview is the most up-to-date analysis on events impacting the healthcare industry. The Macroview updates are part of Decision Resources' Pharmaview product line, which offers a thorough analysis of the biopharmaceutical sector from a therapy, industry and company point-of-view.
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader
in market research publications, advisory services and consulting designed
to help clie
|SOURCE Decision Resources, Inc.|
Copyright©2008 PR Newswire.
All rights reserved